Ifosfamide
Welcome to Dwaey, specifically on Ifosfamide page.
This medicine contains important and useful components, as it consists of
Ifosfamide is available in the market in concentration.
Generic Name of Ifosfamide - Learn More
Ifosfamide
Ifosfamide Precaution - What You Need to Know
- Ifosfamide is a potent chemotherapy agent used primarily in the treatment of cancer. It is essential to consider various precautions before starting treatment, especially in vulnerable populations.
- Pregnancy: Ifosfamide is classified as a pregnancy category D drug, meaning there is evidence of potential harm to the fetus. It should be avoided during pregnancy unless the benefits clearly outweigh the risks. Women who are pregnant or planning to become pregnant should discuss alternative treatments with their doctor.
- Breastfeeding: The drug may pass into breast milk and affect a nursing infant. It is generally recommended to avoid breastfeeding during treatment and for a period afterward.
- Renal and Hepatic Impairment: Patients with existing kidney or liver disease should be closely monitored, as Ifosfamide is metabolized by the liver and excreted by the kidneys. Renal dysfunction, in particular, may lead to an increased risk of toxicities.
- Bone Marrow Suppression: Ifosfamide can cause severe suppression of bone marrow, leading to neutropenia, anemia, and thrombocytopenia. Regular blood tests to monitor white blood cell count, hemoglobin, and platelet levels are necessary.
- Monitoring Parameters: Blood cell counts, kidney function (serum creatinine, BUN), liver function (liver enzymes), and electrolytes (especially sodium and potassium) should be closely monitored throughout therapy.
- Misuse or Dependency: While Ifosfamide is not typically associated with misuse or dependency, it is important to follow the prescribed dosage to prevent toxic accumulation.
Ifosfamide Indication - Uses and Benefits
- Primary Indication: Ifosfamide is primarily used as a chemotherapeutic agent for treating a variety of cancers. It is commonly prescribed for:
- Testicular cancer: Used as part of combination therapy for metastatic testicular cancer.
- Ovarian cancer: It may be utilized in combination with other drugs for the treatment of advanced ovarian cancer.
- Sarcomas: Ifosfamide is also indicated in the treatment of soft tissue sarcomas and osteosarcomas.
- Lymphomas: In specific cases, Ifosfamide is used in the treatment of lymphoma, especially when other treatments fail.
- Off-label Uses: Off-label uses of Ifosfamide include treatment for:
- Bladder cancer: As a part of a combination regimen.
- Breast cancer: In certain metastatic cases, although not a first-line option.
- Neuroblastoma: As part of a combination chemotherapy regimen.
- Evidence-Based Context: The use of Ifosfamide is supported by various clinical guidelines, including those from the National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO), which recommend it in certain chemotherapy regimens for the aforementioned cancers.
Ifosfamide Contraindications - Important Warnings
- Pre-existing Renal Dysfunction: Ifosfamide is contraindicated in patients with severe renal impairment, as it may lead to further renal damage and accumulation of toxic metabolites. Creatinine clearance should be evaluated prior to starting therapy.
- Severe Bone Marrow Suppression: Ifosfamide should not be used in patients with severe bone marrow suppression, as it can exacerbate this condition, leading to dangerous decreases in white blood cells, red blood cells, and platelets.
- Hypersensitivity to Ifosfamide: Any patient who has shown hypersensitivity to Ifosfamide or other alkylating agents should not receive this medication.
- Age Considerations: The drug's use in pediatric populations may be associated with additional risks, including long-term developmental effects, and should be done with extreme caution. In elderly patients, dose adjustments may be necessary due to the increased likelihood of comorbidities and reduced organ function.
- Pregnancy and Breastfeeding: As noted in precautions, Ifosfamide is contraindicated in pregnancy and breastfeeding due to potential risks to the fetus or infant.
- Rationale: These contraindications exist due to the drug's potential for severe toxicity, including renal failure, bone marrow suppression, and teratogenic effects.
Ifosfamide Side Effects - What to Expect
- Common Side Effects:
- Bone marrow suppression: Leads to neutropenia, anemia, and thrombocytopenia, often resulting in an increased risk of infections, fatigue, and bleeding.
- Gastrointestinal disturbances: Nausea, vomiting, and diarrhea are commonly observed in patients undergoing Ifosfamide therapy.
- Cystitis: Bladder irritation and hemorrhagic cystitis can occur, though this can be mitigated with the use of mesna, which protects the bladder from toxic metabolites.
- Hair Loss: Alopecia is common during chemotherapy treatments, including Ifosfamide, and is usually temporary.
- Serious Side Effects:
- Neurotoxicity: Can include symptoms like confusion, seizures, or encephalopathy, which are more common in patients with renal impairment.
- Renal Toxicity: Severe kidney damage, including acute kidney failure, can occur, particularly in those with pre-existing renal issues.
- Cardiotoxicity: Though rare, Ifosfamide can cause heart problems, such as arrhythmias or myocarditis.
- Long-Term Effects: Chronic use of Ifosfamide can lead to secondary cancers, particularly in patients with long-term exposure.
- Management: Supportive care such as antiemetic medications for nausea, hydration, and the use of mesna to protect the bladder can help reduce side effects. Any severe reactions, such as confusion or signs of bleeding, should be immediately reported to a healthcare professional.
Ifosfamide Pregnancy Category ID - Safety Information
4
Ifosfamide Mode of Action - How It Works
- Mechanism of Action: Ifosfamide is an alkylating agent that works by adding an alkyl group to the DNA molecule, which prevents the DNA from being properly replicated and transcribed. This leads to cell death, particularly in rapidly dividing cancer cells.
- Pharmacodynamics: Ifosfamide exerts its cytotoxic effects during the DNA synthesis phase of the cell cycle, specifically by causing cross-links between strands of DNA. This interferes with the replication of the genetic material, which is essential for cancer cell survival and proliferation.
- Pharmacokinetics: Ifosfamide is administered intravenously and is metabolized in the liver to form its active metabolites. It is primarily excreted through the kidneys. The drug has a half-life of approximately 6–7 hours, with its metabolites having a longer duration of action. The use of mesna alongside Ifosfamide helps to reduce its toxic metabolites’ effects on the bladder.
- Therapeutic Benefit: The ability to target rapidly dividing cancer cells while sparing normal cells makes Ifosfamide an effective treatment for various cancers, especially when combined with other chemotherapeutic agents.
Ifosfamide Drug Interactions - What to Avoid
- Drug-Drug Interactions:
- Cyclophosphamide and Other Alkylating Agents: Combining Ifosfamide with other chemotherapy agents like cyclophosphamide may increase the risk of severe myelosuppression. Careful dosing and monitoring are required.
- Anticoagulants (e.g., Warfarin): Ifosfamide may enhance the anticoagulant effect of warfarin, increasing the risk of bleeding. Regular monitoring of INR (International Normalized Ratio) is advised.
- Cisplatin: Concurrent use with cisplatin may increase the risk of nephrotoxicity. Ifosfamide's renal toxicity is compounded when used with cisplatin.
- Food and Alcohol: Alcohol and grapefruit should be avoided while taking Ifosfamide, as they can interfere with the drug's metabolism. Grapefruit may inhibit enzymes that metabolize Ifosfamide, leading to higher drug levels and increased toxicity.
- Clinical Recommendations:
- Avoid combining Ifosfamide with nephrotoxic agents, including non-steroidal anti-inflammatory drugs (NSAIDs), to minimize kidney damage.
- Ensure proper hydration and consider using mesna to prevent bladder toxicity.
- Regular laboratory monitoring of electrolytes, kidney function, and complete blood counts is crucial for early detection of adverse interactions.
Ifosfamide Adult Dose - Recommended Dosage
- Standard Dosing: The typical adult dose of Ifosfamide for the treatment of cancers such as testicular cancer or sarcomas is 1.2 to 2 grams per square meter of body surface area (BSA) daily for 5 consecutive days as part of a chemotherapy regimen.
- Administration Method: Ifosfamide is administered intravenously, with the dose and schedule adjusted based on the type of cancer, the patient’s response, and any adverse reactions.
- Dose Adjustments: In the case of renal dysfunction or severe bone marrow suppression, the dose may need to be reduced or the treatment delayed.
- Maximum Allowable Dose: The total maximum dose of Ifosfamide in a 24-hour period is typically 2 grams per square meter.
- Titration Schedules: The dosage may be adjusted based on the patient’s tolerance, side effects, and the specific clinical scenario.
Ifosfamide Child Dose - Dosage for Children
- Pediatric Dosing: Dosing for children is generally based on body surface area (BSA). Typical dosing is 1.2 to 2 grams per square meter of BSA per day for 5 consecutive days, similar to adult dosing.
- Safety Considerations: The use of Ifosfamide in children is considered only when the benefits outweigh the risks, as the drug can cause long-term developmental and growth issues.
- Efficacy and Monitoring: Children receiving Ifosfamide should be carefully monitored for signs of toxicity, including bone marrow suppression, renal dysfunction, and neurotoxicity. Special attention should be paid to hydration and the use of mesna to prevent bladder toxicity.
- Adjustments: Dosage adjustments may be needed based on the child’s age, weight, and renal function. Pediatric patients may be more susceptible to side effects, so frequent monitoring is crucial.
Ifosfamide Renal Dose - Dosage for Kidney Conditions
- Renal Impairment Considerations: Ifosfamide is primarily excreted through the kidneys, so renal impairment can result in higher drug levels and increased toxicity.
- Dosage Adjustment: In patients with moderate renal impairment (creatinine clearance 30-50 mL/min), the dose may be reduced by 25%. In patients with severe renal impairment (creatinine clearance <30 mL/min), the drug should be used with caution, and dose reductions of up to 50% may be necessary.
- Monitoring: Renal function should be regularly monitored throughout therapy, including serum creatinine and BUN levels, to prevent nephrotoxicity. Patients should be hydrated adequately before and after treatment to minimize the risk of kidney damage.
- Management of Toxicity: Ifosfamide should be discontinued or the dose reduced if signs of nephrotoxicity, such as elevated creatinine, are detected.
